A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
Sequana Medical has just announced additional data on safety, quality of life and survival from its North American alfapump study, called Poseidon which could signal an end to manual draining of ascites.
A study has shown that the use of exhaled volatile organic compounds (VOCs) can be used as biomarkers for differentially identifying liver disease on breath.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.